跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

EHU149801

Sigma-Aldrich

MISSION® esiRNA

targeting human PLK3

登录查看公司和协议定价

UNSPSC代码:
41105324
NACRES:
NA.51

描述

Powered by Eupheria Biotech

质量水平

产品线

MISSION®

形式

lyophilized powder

esiRNA cDNA靶序列

GCAAGCAGTGGAGATGGATTTGAAGAAGGTCTGACTGTGGCCACAGTAGTGGAGTCAGCCCTTTGTGCTCTGAGAAATTGTATAGCCTTCATGCCCCCAGCGGAACAGAACCCGGCCCCCCTGGCCCAGCCAGAGCCTCTGGTGTGGGTCAGCAAGTGGGTTGACTACTCCAATAAGTTCGGCTTTGGGTATCAACTGTCCAGCCGCCGTGTGGCTGTGCTCTTCAACGATGGCACACATATGGCCCTGTCGGCCAACAGAAAGACTGTGCACTACAATCCCACCAGCACAAAGCACTTCTCCTTCTCCGTGGGTGCTGTGCCCCGGGCCCTGCAGCCTCAGCTGGGTATCCTGCGGTACTTCGCCTCCTACATGGAGCAGCACCTCATGAAGGGTGGAGATCTGCCCAGTGTGGAAGAGGTAGAGGTACCTGCTCCGCCCTTGCTGCTGCAGTGGGTCAAGACGGATCAGGCTCTCCTCATGCTGTTTAGTGATGGCACTGTCCAGGTGAACTTCTACGGGGACCAC

基因组数据库 |人类登记号

NCBI登记号

运输

ambient

储存温度

−20°C

基因信息

一般描述

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

法律信息

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mahamat Babagana et al.
Molecular carcinogenesis, 59(1), 5-14 (2019-10-02)
The activation of oncogenic mitogen-activated protein kinase cascade via mutations in BRAF is often observed in human melanomas. Targeted inhibitors of BRAF (BRAFi), alone or as a part of a combination therapy, offer a significant benefit to such patients. Unfortunately
Cecilia Aquino Perez et al.
Cells, 9(6) (2020-06-25)
Polo-like kinases play essential roles in cell cycle control and mitosis. In contrast to other members of this kinase family, PLK3 has been reported to be activated upon cellular stress including DNA damage, hypoxia and osmotic stress. Here we knocked
Chellappagounder Thangavel et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(21), 5468-5482 (2014-08-29)
Perturbations in the retinoblastoma pathway are over-represented in advanced prostate cancer; retinoblastoma loss promotes bypass of first-line hormone therapy. Conversely, preliminary studies suggested that retinoblastoma-deficient tumors may become sensitized to a subset of DNA-damaging agents. Here, the molecular and in

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门